CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer

Expert discussion on key data for CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer including guidance on clinical implementation of shared-decision making with patients.Medscape Medical Affairs
Source: Medscape Today Headlines - Category: Consumer Health News Tags: None Virtual Symposium Source Type: news